Introduction {#Sec1}
============

Local anesthetic infusion techniques have been reported to reduce opiate requirements and pain scores following different kinds of surgery, including orthopedic surgery \[[@CR1], [@CR2]\], inguinal hernia \[[@CR3]\], and Cesarean surgery in women \[[@CR4]\]. Decades ago, wound infiltration with either ropivacaine or bupivacaine was reported as a good pain control approach following surgery \[[@CR5]\]. In the present study, we assessed the hypothesis that PRF-108 and PRF-110 formulations afford prolonged pain relief following surgery.

PRF-108 and PRF-110 are new extended-release oily formulations of ropivacaine and are generally recognized as safe excipients intended for local administration into surgical wounds. The formulations are designed to slowly release the ropivacaine. It is expected that the provision of local analgesia over a long time span will reduce the need for systemic analgesics, especially opiates, and that this may also shorten the hospitalization time. The two formulations are very similar and differ in only a single ingredient, DMPG (1,2-dimyristoyl-sn-glycero-3 phosphoglycerol NH~4~/Na salt). To test this hypothesis, the above formulations were applied to the wound space in an incisional model in pigs \[[@CR6]\].

Methods {#Sec2}
=======

Drugs {#Sec3}
-----

PRF-108 at a concentration of 4% ropivacaine in either 4% ethanol (Group 3) or 6% ethanol (Group 4) or PRF-110 in 6% ethanol was injected sub-cutaneously in the incision area at a volume of 2.5 mL on each side. The ropivacaine hydrochloride solution (Naropin^®^ 1%, AstraZeneca) was diluted in saline to achieve a concentration of 0.5%. Vehicle-treated animals were treated with 6% ethanol/viscous material.

Drug Formulation {#Sec4}
----------------

All drug combinations were prepared by Nextar ChemPharma Ltd., Israel, from the following components: ropivacaine hydrochloride H~2~O (Haorui Pharma-Chem. Inc.), lecithin phospholipon 90G (PL90G; Phospholipid GmbH), castor oil (Spectrum Chemical Mfg. Corp.), cysteine hydrochloride (Spectrum Chemical Mfg. Corp.), absolute ethanol (Merck), and, for PRF-108 only, DMPG (1,2-dimyristoyl-sn-glycero-3 phosphoglycerol NH~4~/Na salt; Avanti). All components met the 'generally recognized as safe' criteria of the Food and Drug Administration.

The composition of 4% ropivacaine PRF-108 was ropivacaine hydrochloride monohydrate 4.78% (w/w), PL90G 50.89% or 48.89% (w/w; 4% or 6% ethanol formulation, respectively), castor oil 35.21% (w/w), cysteine hydrochloride 0.10% (w/w), and ethanol 4% or 6% (w/w). The composition of 4% ropivacaine PRF-110 was ropivacaine HCl monohydrate 4.78% (w/w), PL90G 53.91% (w/w), castor oil 35.21% (w/w), cysteine HCl 0.10% (w/w) and ethanol 6.0% (w/w). Ingredients were weighed and dissolved in excess ethanol, blended by sonication in a pharmaceutical reactor at 50 °C. Sonication was continued for 4 h, and additional 1-h periods if needed, until a clear solution was obtained. The solution was dried in a rotary evaporator (rotor 60 rpm, vacuum 40--200 mbar) and the final alcohol content was corrected to 4% or 6% as indicated.

Animals and Housing {#Sec5}
-------------------

Danish Landrace X large white crossbred weaned male pigs (*n* = 46) from the domestic herd at Lahav Labs (Negev, Israel) were used. Prior to the beginning of the experiment, all animals were kept under conventional pig production conditions. All pigs were 7--8 weeks old and weighed 10 ± 1 kg at the start of the study. The animals were housed in open pens (1.4 × 2.4 m) 7 days prior to study initiation. The pigs were kept in groups of two or three during the acclimatization period and throughout the experiment. Feeding occurred three times daily using special pig food (Dry Sows; Ct \# 5420; Milobar, 7880, Oshrat, Israel), and the pigs were provided opportunities to root and chew for enrichment. Fresh water was provided ad libitum by an automated system. The pigs were kept on a 12-h light/dark cycle. The study was approved by the Institutional Animal Care and Use Committee (IACUC) and adhered to guidelines of the Committee for Research and Ethical Issues of the International Association for the Study of Pain (IASP) \[[@CR7]\]. All tests were performed blind, that is, the technician was unaware of the individual animal's treatment.

Habituation Protocol {#Sec6}
--------------------

The pigs were habituated to the protocol for 5 days prior to surgery. The researchers, the veterinarian, and the animal care technicians played with the pigs in their home pen for at least 15 min, twice a day, on each day of the acclimatization period and throughout the experiment. As a result, the pigs became familiar with their observers. This ensured calm and consistent handling of the animals. The same technicians cared for the animals throughout the entire study period. No other people were allowed into the housing facility. To familiarize the pigs with the protocol and technicians, they were trained to walk to the preparation room daily during the habituation period. The pigs were always returned to their original pens with their original pen mates. The habituation process was intended to reduce the stress level of the pigs.

Anesthesia, Surgery, and Drug Application {#Sec7}
-----------------------------------------

On the day of surgery, the pigs walked freely to the preparation room. The technicians carried each animal in their hands and placed an anesthetic facemask (Stephan Akzent Color) on the pig's mouth and nose. Each animal was anesthetized with a 3% isoflurane/100% oxygen mixture. The technician held the pig until it was relaxed and sleepy. Then, the technician placed the pig in a sternal position, still connected to the anesthesia mask. The pig was shaved and swabbed with 70% ethanol and then carried to the operating room. The pig was placed on the operating table and a sterile environment was maintained. The area of the incision was swabbed with antiseptic liquid polidine solution (Polysept solution, Rekah Pharmaceutical Industry Ltd.) and the non-operated areas were covered with sterile sheets. Blood oxygen saturation was monitored throughout the anesthesia (Spacelab Medical).

The operation is fully detailed in Castel et al. \[[@CR6]\]. Briefly, a 6- to 7-cm incision was made through only the skin and fascia, keeping the muscle intact. The incision was made on the left side of the lower back toward the caudal end. Immediately after the incision was made, the drug was applied to the pocket resulting from the skin incision. Following drug administration, the incisions were closed using 3--0 silk sutures (Assut UK Ltd.) and a continuous suturing technique. Following the incision, all pigs received the antibiotic marbofloxacin (10% w/v; Marbocyl^®^, Vétoquinol UK Ltd.) at a total dose of 0.5 mL per pig, which was administered into the neck muscle via intramuscular injection. Each animal was kept under anesthesia for the duration of the surgery. The entire procedure, from the time that the animal was introduced to the facemask until the facemask was removed, was performed in approximately 20 min. The animals were then returned to their home pen for recovery.

Assessment of Mechanical Sensitivity {#Sec8}
------------------------------------

Mechanical sensitivity was assessed using von Frey filaments \[Touch Test (von Frey) Sensory Evaluator Kit, model 58011, Stoelting Co.\]. The tests were performed in the pig's home pen. Von Frey filaments ranging from a minimum of 1 g (diameter = 0.229 mm; force = 9.804 mN) to a maximum of 60 g (diameter = 0.711 mm; force = 588.253 mN) were used. The intact side (contralateral to the side of incision) was introduced first to the von Frey filaments as a control. The filaments were then applied approximately 0.5 cm proximal to the incision on the skin \[[@CR6]\]. Each filament was applied three times with a 5- to 10-s interval between applications. If withdrawal was not achieved, a thicker filament was applied. If withdrawal was achieved, a thinner filament was applied. By alternating the filaments, the force required to achieve a withdrawal reaction was determined. This procedure was carried out at different time-points during 48 h of post-surgery follow-up.

Incision Healing {#Sec9}
----------------

The incisions of all animals were scored throughout the study period (48 h). Three additional sham-operated animals and three animals treated with PRF using the 6% ethanol formulation were culled 14 days post-administration and the area of the incision was taken for further histology analysis. The incision of these animals was closely observed and scored during these 14 days of follow-up. The score was composed of two categories: redness (0 = normal; 1 = slight redness at the area of the incision; 2 = diffuse redness) and swelling (0 = no swelling; 1 = slight swelling; 2 = pronounced swelling). The final score of each animal was the sum of the scores on each category. The incision area was photographed daily.

At the end of the study, photographs were taken again, the animals were euthanized, and the incision and surrounding areas were taken for histological analysis of wound healing. The skin samples were collected from each wound area such that the surgical incision was located in their center. The samples all had similar dimensions (ca. 5 cm long × 3 cm wide × 2 cm deep) and were individually identified. Their cranial edge was marked with a tissue dye (Davidson Marking System). The samples were then pinned to a flat piece of polystyrene foam to maintain their flat shape and were placed individually into containers with 10% neutral buffered formalin for fixation. The cranial edge was also marked on the polystyrene foam. Each sample was evaluated in three 5-µm paraffin-embedded sections. Sample A was approximately 1 cm from the marked (proximal) edge, sample B was from the middle, and sample C was approximately 1 cm from the contralateral distal edge. The healing of each section of the samples was graded. These healing scores served to determine a grade for the entire sample. The grading was as follows: excellent (4) = full healing via a narrow fibrous scar without significant inflammation; very good (3) = full healing, similar to the above but with some less desirable variations, e.g., wider scar but still discrete and/or mild inflammation; good (2) = full healing with extensive local fibrosis, in some cases with some mononuclear inflammation; and poor (1) = all other types of tissue reactions.

Blood and Wound Liquid Collection {#Sec10}
---------------------------------

Venous blood samples (3.5 mL samples) for measurement of the plasma concentration of ropivacaine were drawn at 13 time-points over a period of 38-h post-test item administration. Blood samples were drawn into cooled test tubes (at approximately 4 °C) pre-loaded with EDTA-K3. Samples were centrifuged within 15 min of sampling in a cooled centrifuge (at approximately 4 °C). The supernatant (plasma) was collected for further analysis.

At 48 h, the animals were culled and the wounds were opened. The wound liquid was collected using a 10G needle and a pre-EDTA-K3 loaded syringe. The liquid was then centrifuged and kept at −80 °C until further analysis.

Analysis of Ropivacaine in PRF-108 and PRF-110 Plasma Samples {#Sec11}
-------------------------------------------------------------

Quantitative analysis of ropivacaine levels in plasma was performed using a HPLC/MS/MS method on a Phenomenex Synergi column 150 × 2 mm, 4 µm, Polar-RP, 80A, P.N. 00F-4336-B0, flow rate 0.35 mL/min, at 40 ± 4 °C, run time 4 min, mobile phase acetonitrile/2.5 mM ammonium acetate/formic acid, 40/60/0.2 v/v/v. Samples were diluted in pig plasma and run against a standard ropivacaine in pig plasma curve.

Study Design {#Sec12}
------------

Animals were assigned to five groups as follows: vehicle-treated animals (Group 1); Naropin-treated group (Group 2); PRF-108 in 4% ethanol (Group 3); PRF-108 in 6% ethanol (Group 4); and PRF-110 in 6% ethanol (Group 5). There were 4--6 animals per group. The study was performed in four parts: part 1, habituation (study day −5 until study day 0); part 2, surgery and drug application; part 3, pain assessment for 48 h; and part 4, blood collection and tissue wound liquid collection (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Study design. The figure shows the study activity over a period of 48 h. However, six additional animals were observed for a period of 14 days at day 14. These animals were culled and the incision area was removed for wound healing analysis

Two additional sham-operated animals and four additional animals were dosed with PRF-108 using the 6% ethanol formulation. These animals were followed for 14 days post-injection. At day 14, the animals were culled and the incision area was taken for further histology analysis of wound healing.

Data Analysis {#Sec13}
-------------

The results are presented as mean ± standard error of the mean. Comparisons between groups were performed using one-way analysis of variance followed by Dunnett's test (GraphPad Prism^®^, GraphPad Software, Inc.) and assuming a normal distribution of data. Pharmacokinetic data were analyzed using the Wilcoxon non-parametric test. A *P* value \<0.05 was considered significant.

Results {#Sec14}
=======

Assessment of pain for a period of 48 h post-surgery and placebo application showed a significant decrease in withdrawal force. At baseline, the withdrawal force of the animals was 60.00 ± 0.00 g. One hour post-dosing, the mean group withdrawal force was as low as 2.80 ± 1.00 g at 3 h post-surgery for the placebo-treated animals (*P* \< 0.05 vs. baseline). This low withdrawal force was also detected on study day 33 (1.67 ± 0.30 g). Treatment with PRF-108 using a formulation of 4% ropivacaine/6% ethanol or 4% ropivacaine/4% ethanol was effective in increasing the withdrawal force at 3 h (35.50 ± 7.7 and 35.50 ± 7.9 g, respectively, *P* \< 0.05 vs. the saline group). Treatment with PRF-110 was as effective as PRF-108 with a formulation of 4% ropivacaine/6% ethanol (Fig. [2](#Fig2){ref-type="fig"}). At 24 h post-surgery, animals treated with 4% ropivacaine/4% ethanol experienced reduction in withdrawal force compared to animals treated with 4% ropivacaine/6% ethanol. However, this change was not significant (16.33 ± 3.8 vs. 35.50 ± 7.9 g, respectively). The mean group withdrawal force for the animals treated with PRF-110 was 34.67 ± 8.4 g at 24 h post-surgery.Fig. 2The effect of PRF-108, PRF-110, and Naropin on withdrawal force following von Frey testing. \**P* \< 0.05 vs. sham-operated animals. *EtOH* ethanol, *Ropi* ropivacaine

Naropin treatment was not as effective as PRF-108 or PRF-110 in increasing the withdrawal force. At 3 h post-application, treatment with Naropin resulted in a mean group withdrawal force of 23.50 ± 7.6 g. At 8 h post-Naropin application, there was no significant difference between the withdrawal force of the saline-treated group and the Naropin-treated group. In comparison, the duration of analgesia following treatment with PRF-108 or PRF-110 was 30--33 h (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3The effect of PRF-108, PRF-110 and Naropin on the duration of analgesia. PRF-108 and PRF-110 showed a significantly lower analgesia period, exceeding 24 h, vs. Naropin. \**P* \< 0.05 vs. sham-operated animals. *EtOH* ethanol, *Ropi* ropivacaine

A pharmacokinetic study exploring the level of ropivacaine in the plasma following treatment with either PRF-108 or Naropin suggested no difference in the maximum plasma concentration (*C*~max~) between PRF-108 and Naropin (2919 vs. 3162 ng/mL, respectively; Fig. [4](#Fig4){ref-type="fig"}). A *P* value of 0.0520 was found when comparing the time at which *C*~max~ was observed (*T*~max~) for PRF-108 and Naropin (6.50 vs. 0.5 h, respectively; Table [1](#Tab1){ref-type="table"}). Forty-eight hours post-dosing, analysis of the blood ropivacaine concentration showed a very low level of ropivacaine following treatment with PRF-108, PRF-110, or Naropin. No difference was found between the levels of ropivacaine in the animals treated with PRF-108 using 6% ethanol versus the 4% ethanol formulation (102 ± 34 vs. 70 ± 20 ng/mL). No difference was found between PRF-110 and PRF-108 using the 6% ethanol formulation (31 ± 5 vs. 102 ± 34 ng/mL). The area under the curve of the plasma concentration of ropivacaine demonstrated a significant increase following PRF-108 (44,579 ± 3662) versus Naropin (5918 ± 1008; *P* \< 0.05) administration (Table [1](#Tab1){ref-type="table"}). Analysis of the wound fluid revealed no significant difference in the ropivacaine concentration between the following treatment groups: PRF-108 4% ropivacaine/4% ethanol, PRF-108 4% ropivacaine/6% ethanol, and PRF-110. A comparison of the wound concentration of ropivacaine in the PRF-treated and the Naropin-treated groups showed a significantly higher concentration in animals treated with 4% ropivacaine/6% ethanol and PRF-110 (7777 ± 2822 and 3799 ± 599 ng/mL, respectively, vs. 15 ± 13 ng/mL, *P* \< 0.05; Fig. [5](#Fig5){ref-type="fig"}b). However, the ratio of the ropivacaine concentration in the wound fluid versus the ropivacaine blood concentration at 48 h post-dosing was higher after treatment with PRF-110 or PRF-108 than following treatment with Naropin (Fig. [5](#Fig5){ref-type="fig"}c).Fig. 4Changes in ropivacaine plasma levels over time following PRF-108 or Naropin dosingTable 1Pharmacokinetic data of Naropin and PRF-108*C* ~max~ (ng/mL)*T* ~max~ (h)AUC~last~AUC~inf~*T* ~1/2~ (h)Naropin 0.5% *N*44444 Mean2314.250.505917.695939.672.69 SD739.670.002016.352030.440.22 Median2283.000.505879.135898.402.68 Min1530.000.503574.753581.982.49 Max3161.000.508337.758379.892.92 Lower 95% CI1137.282709.232708.792.34 Upper 95% CI3491.229126.149170.553.05PRF-108 *N*44444 Mean2318.506.5044,578.8147,182.3310.93 SD457.056.357323.907349.252.47 Median2262.006.5045,325.8847,750.0410.93 Min1831.001.0036,054.0038,571.238.13 Max2919.0012.0051,609.5054,658.0013.74 Lower 95% CI1591.23−3.6132,924.8535,488.027.00 Upper 95% CI3045.7716.6156,232.7758,876.6314.87*P* valueNS0.05200.06710.06710.0671*AUC* ~*inf*~ area under curve extrapolated to infinity from dosing time, based on the last observed concentration, *AUC* ~*last*~ area under curve last: from dosing to last measurable concentration, *CI* confidence interval, *C* ~*max*~ maximum plasma concentration, *NS* not significant, *SD* standard deviation, *T* ~*1/2*~ half-life, *T* ~*max*~ time at which *C* ~max~ was observedFig. 5Concentration of ropivacaine in the plasma (**A**) and the wound (**B**) 48 h post-treatment with PRF-108/4% ethanol, PRF-108/6% ethanol, PRF-110 or Naropin. \**P* \< 0.05 vs. the Naropin-treated group. *EtOH* ethanol, *Ropi* ropivacaine

No abnormalities were noticed during the 48-h observation of the incision in any of the treatment groups during the 14 days of wound observation. No swelling or redness was noted. At 14 days post-dosing, the wounds of four additional animals treated with PRF-108 in 6% ethanol formulation and two sham-operated animals were harvested. Gross observation of the incisions suggests a clean and almost full incision bridge with no difference between the sham-operated animals and the PRF-108 in 6% ethanol-dosed animals (Fig. [6](#Fig6){ref-type="fig"}). Table [2](#Tab2){ref-type="table"} details the histological findings. The total histology score of the PRF-108 in 6% ethanol group ranged between 2 and 4. In comparison, the total scores of the sham-operated animals ranged between 2 and 3. Overall, the histology analysis suggests that treatment with PRF-108 in 6% ethanol did not affect the healing process.Fig. 6Representative photographs of macroscopic observations. **a** A 7.5-cm-long sample from an animal treated with 4% ropivacaine/6% ethanol (Group 3). The incision is well apposed and visible up to a point. Sutures continue for approximately 1.8 cm beyond the visible incision (*marked*). Small dried scabs in suture holes and to a lesser degree along the entire visible incision. No thickening is noted. **b** A sample from an animal of the sham group (Group 1) with an 8.4-cm-long incision. The incision is well apposed and visible throughout, except in the 1 cm away from the mark where it is barely perceptible (*marked*). A slightly larger scab in approximately one-third of the incision line and small dried scabs limited to suture holes. No thickening is notedTable 2Histology observations of the incision 14 days post-incision/dosingGroup number and treatmentAnimal numberSampleEpidermisDermis + SCSummary (score)Group 3 PRF-108/6% ethanol5AFE with a pustuleExcellentExcellent healing (4)BFEExcellentCFE with a pustuleExcellent6AFE with a pustuleA narrow discrete scar; in the deep dermis and SC wider scarring with mild mononuclear inflammation (very good--excellent)Excellent healing (4)BFE with a pustuleA narrow discrete scar; a large pustule nearby probably at suture entry (excellent)CFE with a pustuleA narrow discrete scar; a large pustule nearby probably at suture entry (excellent)7A--A scar is not identified, complete healingVery good healing (3)BFE with pustuleA narrow discrete scar; near it a suture tract, below it a small focus of granulomatous and lesser neutrophilic inflammation with some amphophilic material (good)CHF with pustuleA narrow scar; no inflammation (excellent)8AHF with pustuleA somewhat wide area of fibrosis in dermis and SC, suture cavity, minimal inflammation (very good)Good--very good healing (2--3)BHF with pustuleScar not clearly identified, an area of fibrosis in deep dermis with an epidermal inclusion (from suture) and mild inflammation (good--very good)CHF with pustuleA somewhat wide area of fibrosis in dermis and SC, multifocal mild to moderate mononuclear inflammation in SC (good)Group 1 sham-operated animals9AHF with pustuleA narrow scar in deep dermis to HF, mild fibrosis in SC, a small suture tract (excellent)Good healing (2)^a^BHF with pustuleA narrow fibrous scar immediately next to a suture tract with many neutrophils, suggestive of bacterial infection (poor)CFE, large pustulesA discrete scar is not identified; moderate fibrosis without inflammation (good)10AFE with pustuleA somewhat wide scar without inflammation (very good)Very good healing (3)BFE, large pustulesModerate fibrosis in dermis and SC with minimal inflammation, suture tract (good)CFE with pustuleA narrow and discrete scar, next to it a tract (excellent)Each sample was evaluated in three sections: sample A is approximately 1 cm from the marked (proximal) edge; sample B is from the middle; sample C is approximately 1 cm from the contralateral distal edge*FE* fully epithelialized, *HF* hair follicle, *SC* subcutis/subcutaneous^a^Neutrophilic infiltration suggestive of the presence of bacterial infection

Discussion {#Sec15}
==========

The current study was designed to investigate the activity of local treatment with PRF-108 or PRF-110 using the post-operative pain model in pigs. The activity of these formulations was compared to the commercially available ropivacaine solution, Naropin. An additional aim was to assess the significance of differences in the ethanol content in the final formulation on its efficacy and pharmacokinetics. All formulations in this study contained 4% ropivacaine. The data show: (1) a significantly better analgesic effect of PRF-108 and PRF-110 vs. Naropin. (2) The duration of analgesia of PRF-108 and PRF-110 was significantly longer than that of Naropin. (3) A significantly longer Tmax of PRF-108 vs. Naropin. (4) At 48 h post-application, the wound concentration of ropivacaine was a hundred times higher following treatment with PRF-108 or PRF-110 vs. treatment with ropivacaine. (5) No difference was found between PRF-108 in 4% ethanol formulation vs. PRF-108 using 6% ethanol.

There is extensive evidence suggesting that pigs' skin resembles the human skin in structure, function \[[@CR8], [@CR9]\], innervation \[[@CR10]\] and response to mechanical and thermal stimulation \[[@CR6], [@CR11]--[@CR13]\]. Additionally, pigs have become a standard wound healing model due to the similarities to humans, including re-epithelialization rather than contraction \[[@CR14]\]. Indeed, the level and duration of the effect of a single dose of Naropin are in line with what was found in humans. A double-blind randomized trial of wound infiltration with ropivacaine after breast cancer surgery with axillary node dissection suggests significant pain relief for 6 h post-treatment \[[@CR15]\]. Pharmacokinetic studies in humans following spinal ropivacaine administration show a plasma peak at 0.5 h post-administration and at 4 h post-administration the level of ropivacaine in the plasma was greatly reduced \[[@CR16]\]. This is in line with the data described in this work. Continuous wound infusion of ropivacaine results in a longer presence of ropivacaine in the blood that is dependent on the duration of the infusion. The advantage of a local infusion is the relatively low systemic exposure \[[@CR17]\]. A recent comparison between the post-operative analgesia using local anesthetics such as ropivacaine or bupivacaine following a continuous wound infusion approach with traditional patient-controlled analgesia (PCA) suggests that continuous wound infusion is as effective for post-operative analgesia as traditional PCA. Furthermore, this therapy reduced the incidences of drowsiness, dizziness, respiratory depression and decreased the intensive care unit stay and hospital expenditure \[[@CR18], [@CR19]\]. These studies emphasize the importance of prolonged ropivacaine activity immediately post-surgery. A study with a patient who underwent posterior lumber instrumented fusion for degenerative disc disease suggests that routine use of epidural infusion anesthesia for lumbar spine surgery has too many risks and offers very little advantages over PCA \[[@CR20]\]. Gulle et al. \[[@CR21]\] also showed that a combination of epidural ropivacaine and oral oxycodone can reduce the pruritus which is often reported following epidural analgesia with bupivacaine, epinephrine and fentanyl after lumbar fusion surgery. In knee arthroplasty surgery, local injection of analgesics periarticularly at the end of the operation and intraarticularly at 21 h post-operatively provided excellent pain relief and earlier home discharge. In addition, the authors reported a high degree of patient satisfaction after 6 months \[[@CR2]\]. The current study shows that a single dose of PRF-108 or PRF-110, a slow-release ropivacaine formulation, has a prolonged analgesic effect which can be detected for up to 30 h, without the need for additional dosing. Local dosing of PRF-108 and PRF-110 immediately before closure of the surgery wound has the advantages of prolonged ropivacaine activity and balancing the infusion catheterization risk.

In this study, four additional animals were operated and injected with PRF-108 using the 6% ethanol formulation. Ethanol is known to interfere with wound healing. Most studies refer to the effect of systemic exposure to ethanol as an inhibition factor in wound healing. It is suggested that early dermal inflammatory responses, including MPO activity, production of MIP-2, KC, and IL-1beta, are impaired in mice given ethanol before injury, which may also have detrimental effects on later stages of wound healing \[[@CR22]\]. We therefore observed the incision healing process in the group that was exposed to the formulation containing the higher ethanol percentage. Our data suggest no effect of this formulation on incision healing and closure.

Conclusions {#Sec16}
===========

This study suggests that PRF-108 and PRF-110 clearance from the wound is slower than that of the commercial ropivacaine solution. This can explain the high efficacy and prolonged duration of activity of these formulations compared to Naropin. It also suggests that an ethanol concentration of up to 6% does not affect the efficacy or clearance. Gross observations and detailed histology analysis suggest that the 6% formulation had no detrimental effects on incision healing. The low concentration of ropivacaine found in the blood following treatment with PRF-108 or PRF-110 suggests that the source of the analgesic activity was due to the high ropivacaine concentration found locally in the wound fluid and was not due to systemic exposure.
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